CA2729351C - Fn14/trail fusion proteins - Google Patents

Fn14/trail fusion proteins Download PDF

Info

Publication number
CA2729351C
CA2729351C CA2729351A CA2729351A CA2729351C CA 2729351 C CA2729351 C CA 2729351C CA 2729351 A CA2729351 A CA 2729351A CA 2729351 A CA2729351 A CA 2729351A CA 2729351 C CA2729351 C CA 2729351C
Authority
CA
Canada
Prior art keywords
trail
cells
cancer
domain
tweak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2729351A
Other languages
English (en)
French (fr)
Other versions
CA2729351A1 (en
Inventor
Marjaneh Razmara
Mark L. Tykocinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of CA2729351A1 publication Critical patent/CA2729351A1/en
Application granted granted Critical
Publication of CA2729351C publication Critical patent/CA2729351C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2729351A 2008-06-30 2009-06-30 Fn14/trail fusion proteins Active CA2729351C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13353208P 2008-06-30 2008-06-30
US61/133,532 2008-06-30
PCT/US2009/003886 WO2010005519A1 (en) 2008-06-30 2009-06-30 Fn14/trail fusion proteins

Publications (2)

Publication Number Publication Date
CA2729351A1 CA2729351A1 (en) 2010-01-14
CA2729351C true CA2729351C (en) 2017-01-24

Family

ID=41278748

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2729351A Active CA2729351C (en) 2008-06-30 2009-06-30 Fn14/trail fusion proteins

Country Status (9)

Country Link
US (3) US8039437B2 (enExample)
EP (2) EP2297198B1 (enExample)
JP (1) JP5475766B2 (enExample)
CN (1) CN102137869B (enExample)
AU (1) AU2009269141B2 (enExample)
CA (1) CA2729351C (enExample)
IL (1) IL210175A0 (enExample)
SG (1) SG191698A1 (enExample)
WO (1) WO2010005519A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011091181A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
AU2011207253B2 (en) 2010-01-20 2015-02-12 Merck Sharp & Dohme Corp. Anti-ILT5 antibodies and ILT5-binding antibody fragments
PL391627A1 (pl) * 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
WO2012042480A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies
PL219845B1 (pl) * 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
CN102206281B (zh) * 2011-03-28 2014-04-09 中国人民解放军第三军医大学第一附属医院 融合蛋白tetph、表达载体及其构建方法
WO2012145568A1 (en) 2011-04-21 2012-10-26 Albert Einstein College Of Medicine Of Yeshiva University Antibodies to human b7x for treatment of metastatic cancer
PL397167A1 (pl) * 2011-11-28 2013-06-10 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
US9873747B2 (en) 2013-01-31 2018-01-23 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
WO2014121099A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
US9657082B2 (en) 2013-01-31 2017-05-23 Thomas Jefferson University PD-L1 and PD-L2-based fusion proteins and uses thereof
US9797882B2 (en) 2013-07-09 2017-10-24 The Translational Genomics Research Institute Method of screening for a compound for inhibitory activity of FN14-tweak interaction
EP3019874B1 (en) * 2013-07-09 2019-08-21 The Translational Genomics Research Institute Compositions and methods of screening for compounds that modulate activity at a tweak binding site on a crd of fn14
EP3191131A4 (en) 2014-08-21 2018-09-05 The General Hospital Corporation Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
WO2016139668A2 (en) * 2015-03-03 2016-09-09 Kahr Medical (2005) Ltd Dual signaling protein (dsp) fusion proteins, and methods of using thereof for treating diseases
IL295423B2 (en) 2015-10-01 2023-11-01 Heat Biologics Inc Compounds and methods for joining extracellular complexes of type 1 and 2 as heterologous chimeric proteins
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
KR102597943B1 (ko) 2017-01-05 2023-11-06 카 메디컬 리미티드 Pd1-41bbl 융합 단백질 및 이의 이용 방법
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
HUE057326T2 (hu) 2017-01-05 2022-04-28 Kahr Medical Ltd SIRP1 Alfa-41 BBL fúziós fehérje és eljárások annak alkalmazására
US11267856B2 (en) 2017-02-27 2022-03-08 Shattuck Labs, Inc. CSF1R-CD40L chimeric proteins
CN110290798B (zh) 2017-02-27 2024-04-05 沙塔克实验室有限公司 基于vsig8的嵌合蛋白
IL313003A (en) 2017-02-27 2024-07-01 Shattuck Labs Inc Tigit- and light-based chimeric proteins
CN118852460A (zh) * 2017-12-28 2024-10-29 尤利乌斯·马克西米利安维尔茨堡大学 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA)
CA3104780A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
CA3104778A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. Pd1-4-1bbl variant fusion protein and methods of use thereof
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
WO2021005599A1 (en) 2019-07-11 2021-01-14 Kahr Medical Ltd. Heterodimers and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
JP5148795B2 (ja) * 1999-12-20 2013-02-20 イミュネックス・コーポレーション Ｔｗｅａｋ受容体
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
US7378089B2 (en) 2001-10-02 2008-05-27 The Board Of Trustees Of The Leland Stanford Junior University Gene therapy for the prevention of autoimmune disease
MXPA04009683A (es) * 2002-04-09 2005-01-11 Biogen Idec Inc Metodos para el tratamiento de condiciones relacionadas a tweak.
DK1558640T3 (da) * 2002-10-29 2011-07-25 Anaphore Inc Trimerbindende proteiner til trimer-cytokiner
WO2005010045A1 (en) * 2003-07-24 2005-02-03 Amgen Inc. Compositions and methods relating to multimeric and oligomeric soluble fragments of the tweak receptor
US7285522B2 (en) 2004-08-25 2007-10-23 The Clorox Company Bleaching with improved whitening

Also Published As

Publication number Publication date
EP2297198B1 (en) 2014-12-17
AU2009269141A1 (en) 2010-01-14
US8329657B2 (en) 2012-12-11
SG191698A1 (en) 2013-07-31
CN102137869B (zh) 2018-07-06
CN102137869A (zh) 2011-07-27
EP2297198A1 (en) 2011-03-23
EP2460827A1 (en) 2012-06-06
CA2729351A1 (en) 2010-01-14
AU2009269141B2 (en) 2013-04-04
JP5475766B2 (ja) 2014-04-16
WO2010005519A1 (en) 2010-01-14
US8039437B2 (en) 2011-10-18
US20130065815A1 (en) 2013-03-14
IL210175A0 (en) 2011-03-31
US20120028909A1 (en) 2012-02-02
US20100048478A1 (en) 2010-02-25
JP2011526891A (ja) 2011-10-20

Similar Documents

Publication Publication Date Title
CA2729351C (en) Fn14/trail fusion proteins
US9657082B2 (en) PD-L1 and PD-L2-based fusion proteins and uses thereof
US9221895B2 (en) OX40/TRAIL fusion proteins
Kucka et al. Receptor oligomerization and its relevance for signaling by receptors of the tumor necrosis factor receptor superfamily
US6313269B1 (en) Tumor necrosis factor related receptor, TR6
EP1908780B1 (en) Novel chimeric proteins and methods for using the same
NO331683B1 (no) Anvendelse av et spesifikt polypeptid eller antistoff mot dette for fremstilling av et medikament til behandling av tumorceller som uttrykker APRIL.
Zhou et al. Immunobiology of tumor necrosis factor receptor superfamily
CA2428242A1 (en) Human tumor necrosis factor receptor
CA2221830A1 (en) Tumor necrosis factor related receptor, tr6
WO2020146423A1 (en) Multi-functional fusion proteins and uses thereof
CA2978526A1 (en) Dual signaling protein (dsp) fusion proteins, and methods of using thereof for treating diseases
US20160347846A1 (en) Fusion proteins for modulating regulatory and effector t cells
Holler et al. Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors
Gardnerova et al. The use of TNF family ligands and receptors and agents which modify their interaction as therapeutic agents
Grell et al. TNF and TNF receptor superfamily
Grell et al. Max Plank-Institute for Physiological and Clinical Research, Bad Nauheim, Germany
MXPA01006938A (en) SOLUBLE RECEPTOR BR43x2 AND METHODS OF USING

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140530